BioDelivery Sciences International Inc. (BDSI) Trading 0.8% Higher
BioDelivery Sciences International Inc. (NASDAQ:BDSI)’s share price traded up 0.8% during mid-day trading on Wednesday . The company traded as high as $2.47 and last traded at $2.45, with a volume of 233,232 shares. The stock had previously closed at $2.43.
A number of equities analysts have recently issued reports on the company. Zacks Investment Research upgraded BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research note on Tuesday, July 5th. Janney Montgomery Scott reiterated a “hold” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Tuesday, July 12th. Cantor Fitzgerald reiterated a “hold” rating on shares of BioDelivery Sciences International in a research report on Saturday, July 9th. Piper Jaffray Cos. reiterated a “sell” rating and set a $4.00 target price on shares of BioDelivery Sciences International in a research report on Wednesday, August 10th. Finally, FBR & Co lifted their target price on BioDelivery Sciences International from $9.00 to $12.00 and gave the company an “outperform” rating in a research report on Wednesday, May 4th. One analyst has rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $8.25.
The firm’s market cap is $130.88 million. The company’s 50-day moving average is $2.55 and its 200 day moving average is $2.87.
BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.31). During the same period in the previous year, the company posted ($0.37) earnings per share. The business had revenue of $5 million for the quarter, compared to analyst estimates of $3.35 million. The business’s revenue for the quarter was up 194.1% on a year-over-year basis. Analysts predict that BioDelivery Sciences International Inc. will post ($1.14) EPS for the current fiscal year.
In other news, Director William B. Stone sold 16,000 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was sold at an average price of $2.57, for a total transaction of $41,120.00. Following the transaction, the director now directly owns 122,675 shares of the company’s stock, valued at $315,274.75. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.